Markers of response to platinum-based chemotherapy in lung cancer

被引:4
作者
Barr, Martin P. [1 ]
MacDonagh, Lauren [1 ]
O'Byrne, Kenneth J. [1 ,2 ]
机构
[1] St James Hosp, Trinity Ctr Hlth Sci, Inst Mol Med, Thorac Oncol Res Grp, Dublin 8, Ireland
[2] Queensland Univ Technol, Canc Ageing Res Program, Brisbane, Qld, Australia
关键词
D O I
10.2217/LMT.13.18
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Non-small-cell lung cancer (NSCLC) is the most common cause of cancer-related deaths among men and women worldwide. Despite the development of molecular targeted therapies, platinum-based combination chemotherapy remains the most effective systemic chemotherapy for NSCLC patients. Unfortunately, the outcomes of platinum-based therapies, in particular those containing cisplatin, have reached a plateau due to the development of both intrinsic and acquired resistance. While significant variations in response to platinum-based chemotherapeutic regimens exist, defining molecular features that may determine resistance or response to chemotherapy is critical. This review will focus on some of the emerging biomarkers that are predictive of response to such treatments that may offer potential in the future management of NSCLC patients.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 95 条
[22]   Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard [J].
Fan, SJ ;
Chang, JK ;
Smith, ML ;
Duba, D ;
Fornace, AJ ;
OConnor, PM .
ONCOGENE, 1997, 14 (18) :2127-2136
[23]   Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group [J].
Fossella, F ;
Pereira, JR ;
von Pawel, J ;
Pluzanska, A ;
Gorbounova, V ;
Kaukel, E ;
Mattson, KV ;
Ramlau, R ;
Szczesna, A ;
Fidias, P ;
Millward, M ;
Belani, CP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3016-3024
[24]   Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].
Fossella, FV ;
DeVore, R ;
Kerr, RN ;
Crawford, J ;
Natale, RR ;
Dunphy, F ;
Kalman, L ;
Miller, V ;
Lee, JS ;
Moore, M ;
Gandara, D ;
Karp, D ;
Vokes, E ;
Kris, M ;
Kim, Y ;
Gamza, F ;
Hammershaimb, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362
[25]  
Furuta T, 2002, CANCER RES, V62, P4899
[26]   The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer [J].
Gajra, A ;
Tatum, AH ;
Newman, N ;
Gamble, GP ;
Lichtenstein, S ;
Rooney, MT ;
Graziano, SL .
LUNG CANCER, 2002, 36 (02) :159-165
[27]   Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial [J].
Gandara, DR ;
Vokes, E ;
Green, M ;
Bonomi, P ;
Devore, R ;
Comis, R ;
Carbone, D ;
Karp, D ;
Belani, C .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :131-135
[28]   Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers [J].
Harada, T ;
Ogura, S ;
Yamazaki, K ;
Kinoshita, I ;
Itoh, T ;
Isobe, H ;
Yamashiro, K ;
Dosaka-Akita, H ;
Nishimura, M .
CANCER SCIENCE, 2003, 94 (04) :394-399
[29]   The DNA damage response: Ten years after [J].
Harper, J. Wade ;
Elledge, Stephen J. .
MOLECULAR CELL, 2007, 28 (05) :739-745
[30]  
Hinoshita E, 2000, CLIN CANCER RES, V6, P2401